Engineering toxins for 21st century therapies

FEBS Journal

Volumn 278, Issue 6, 2011, Pages 899-904

  Chaddock, John A ^a   Acharya, K Ravi ^b  

^a SYNTAXIN LTD   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

biotechnology; botulinum neurotoxin; innovation; therapy; toxin

Indexed keywords

ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN C; BOTULINUM TOXIN D; CAPSAICIN; CELL SURFACE MARKER; COAT PROTEIN COMPLEX I; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; OMEGA CONOTOXIN MVIIA; RESINIFERATOXIN; SNARE PROTEIN; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; CONFERENCE PAPER; DRUG BINDING SITE; DRUG DESIGN; DRUG INDUSTRY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENDOSOME; GRAFT VERSUS HOST REACTION; HEALTH CARE ORGANIZATION; HUMAN; LIVER TOXICITY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; T CELL LYMPHOMA; UNITED KINGDOM; VASCULAR DISEASE; VASCULAR LEAKAGE SYNDROME; WORKSHOP;

ANIMALS; DRUG DESIGN; HUMANS; PROTEIN ENGINEERING; TOXINS, BIOLOGICAL;

EID: 79952528150     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08013.x     Document Type: Conference Paper

References (8)

1. Carruthers A, &, Carruthers J, (2008) Botulinum toxin products overview. Skin Therapy Lett 13, 1-4.
2. Turton K, Chaddock JA, &, Acharya KR, (2002) Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 27, 552-558. (Pubitemid 35335403)
3. Foss FM, (2000) DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 1, 110-116.
4. Kreitman RJ, (2006) Immunotoxins for targeted cancer therapy. AAPS J 8, E532-E551. (Pubitemid 44321317)
5. Mathew M, &, Verma RS, (2009) Humanized immunotoxins-a new generation of immunotoxins. Cancer Sci 100, 1359-1365.
6. Nagata S, &, Pastan I, (2009) Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev 61, 977-985.
7. Wiley RG, &, Lappi DA, (2003) Targeted toxins in pain. Adv Drug Deliv Rev 55, 1043-1054. (Pubitemid 37288987)
8. Lacy DB, Tepp W, Cohen AC, DasGupta BR, &, Stevens RC, (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5, 898-902. (Pubitemid 28467413)